Call: 954-398-4474

Know Labs Fortifies its Medical and Scientific Advisory Board

Know Labs Fortifies its Medical and Scientific Advisory Board

Industry Pioneers Enhance Diabetes Management Expertise and FDA Insights

Know Labs, Inc. (NYSE American: KNW) embarks on a new phase with the appointment of four distinguished members to its esteemed Medical and Scientific Advisory Board.

The addition of Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg augments the board’s reservoir of clinical diabetes management expertise and FDA proficiency.

Who’s Joining the Advisory Board?

Jeff Hitchcock, Founder, President, and CEO of Children with Diabetes (CWD), is an Honorary Member of the International Society for Pediatric and Adolescent Diabetes (ISPAD). His pivotal work commenced in 1995 in response to his daughter’s T1D diagnosis.

Must Read CGMs in noncritical care hospitals optimizes glycemic control

Hitchcock’s organization, CWD, provides invaluable resources, expert guidance, and unwavering support to families grappling with T1D.

Karmeen Kulkarni, MS, RD, BC-ADM, CDCES, an acclaimed diabetes care and education specialist, is lauded for her international recognition in nutrition and diabetes management.

Her contributions span a multitude of national awards, including those from the American Dietetic Association and American Diabetes Association.

Kulkarni’s expertise encompasses coordinating the Diabetes Center at St. Mark’s Hospital and pioneering advancements in continuous glucose monitoring at Abbott Diabetes Care.

Dr. Meng Tan, M.D., currently Professor Emeritus of Internal Medicine at the University of Michigan, brings a wealth of experience from his tenure at Dalhousie University, Harvard University’s Joslin Diabetes Center, and Eli Lilly and Company.

His leadership roles in diabetes organizations and vast research experience emphasize his commitment to advancing diabetes management technologies.

Satish Garg, M.D., Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes (BDC), University of Colorado School of Medicine, boasts a rich legacy of over 350 published manuscripts and trailblazing contributions to diabetes care.

Dr. Garg’s achievements encompass pivotal research leading to FDA-approved Continuous Glucose Monitors (CGMs) and groundbreaking closed-loop systems.

Tip: Please fill out the form if you or a friend would like more information on glucose monitoring devices.

A Cohesive Vision for Advancement

Chaired by Know Labs’ Chief Medical Officer, Dr. James H. “Andy” Anderson, the Medical and Scientific Advisory Board will provide strategic guidance.

Their collective expertise is pivotal as Know Labs endeavors to transition from laboratory trials to clinical testing and FDA clearance for their revolutionary non-invasive continuous glucose monitor.

Don’t miss the Guide about Wegovy Dosage Guide: The Best Way For Weight Loss

Know Labs’ Future and Mission

Ron Erickson, CEO, and Chairman at Know Labs, expressed enthusiasm about expanding the Advisory Board with these esteemed experts.

“Their shared passion for advancing diabetes management resonates with Know Labs’ core mission,”

remarked Erickson.

These experts will play an instrumental role in driving ongoing clinical research and understanding the distinct needs of patient populations supported by Know Labs’ innovative device.

Also, read about Dexcom G6 and Google Pixel 6 Compatibility

About Know Labs, Inc.

Know Labs, Inc. (NYSE American: KNW) is a publicly traded company pioneering non-invasive medical diagnostic technology. Trading on the NYSE American Exchange under the stock symbol “KNW,” Know Labs utilizes spectroscopy to capture unique molecular signatures, integrating this patented technology into various wearable, mobile, or bench-top form factors.

The company’s primary application focuses on a non-invasive glucose monitor poised to offer real-time, accessible, and affordable blood glucose level information, subject to U.S. Food and Drug Administration clearance.

Cautionary Note

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Investors are cautioned that these statements involve risks and uncertainties beyond Know Labs, Inc.’s control.

The Company advises reviewing its SEC filings for additional risk factors. Know Labs, Inc. does not commit to any obligation to update statements that are considered to be forward-looking.